Silk Road Medical Stock Price, News & Analysis

Silk Road Medical, Inc. (NASDAQ: SILK) announced it will report its financial results for Q4 and full year 2020 on March 1, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, accessible via phone and webcast. Silk Road Medical specializes in reducing stroke risks with its TransCarotid Artery Revascularization (TCAR) procedure, aimed at treating carotid artery blockages. Investors can find additional information on the company’s website and through investor relations contacts.

Silk Road Medical, Inc. (NASDAQ: SILK) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. Management is set to present on January 12, 2021, at 11:40 a.m. Eastern Time. The live and archived webcast can be accessed in the 'Investors' section on their website. Silk Road Medical is dedicated to reducing stroke risks, notably through their flagship procedure, TransCarotid Artery Revascularization (TCAR), which effectively treats carotid artery blockages.

Silk Road Medical (NASDAQ: SILK) has appointed Kevin Ballinger to its Board of Directors, effective immediately, while Ruoxi Chen has resigned. Ballinger, the CEO of Aldevron and a former executive at Boston Scientific, brings extensive experience in the medical device industry, particularly in interventional cardiology. Under his leadership, Boston Scientific's cardiology division grew to a $3 billion global business. The company aims for significant growth with Ballinger's strategic expertise as it continues to innovate in carotid artery disease treatment.

Silk Road Medical (SILK) reported Q3 2020 revenues of $20.1 million, an 18% increase from the prior year, driven by a commitment to stroke risk reduction. Gross profit rose to $14.6 million, although gross margin decreased to 73% from 76% due to COVID-19 impacts and production variances. Operating expenses increased by 18% to $23.9 million, leading to a net loss of $10.3 million or $0.31 per share, compared to a loss of $8.0 million or $0.26 per share year-over-year. The company is cautious about providing 2020 guidance due to pandemic uncertainty.

Silk Road Medical (Nasdaq: SILK) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 3:20 p.m. Eastern Time. The company aims to reduce stroke risks through its TransCarotid Artery Revascularization (TCAR) procedure, which addresses carotid artery blockages. Interested individuals can access the live or archived webcast of the presentation through the company's website. This event highlights Silk Road Medical's commitment to improving patient outcomes and enhancing clinical practices.

Silk Road Medical, Inc. (NASDAQ: SILK) announced it will release its third quarter 2020 financial results after market close on November 10, 2020. A conference call for investors will follow at 1:30 PM PT / 4:30 PM ET. Participants can join by calling (844) 883-3861 for domestic or (574) 990-9820 for international access, using conference ID 3146919. The company focuses on reducing stroke risk through its flagship TransCarotid Artery Revascularization (TCAR) procedure, which effectively treats carotid artery blockages.

Silk Road Medical, Inc. (Nasdaq: SILK) has appointed Rick Anderson, a seasoned professional with over 30 years in the medical device sector, to its board of directors. Anderson, Chairman of Revival Healthcare Capital, has previously led major companies like ConvaTec Group Plc, enhancing shareholder value through strategic growth initiatives. His extensive experience includes pioneering the first drug-eluting stent. CEO Erica Rogers expressed optimism about Anderson’s guidance in advancing the company's efforts to prevent strokes through TransCarotid Artery Revascularization (TCAR).

Silk Road Medical, Inc. (NASDAQ: SILK) is enhancing its leadership structure with two key appointments. William Whealon, Ph.D., has joined as Executive Vice President of Research and Development, effective immediately, while Lucas Buchanan, currently the CFO, will take on the additional role of Chief Operating Officer starting October 1, 2020. Dr. Whealon brings over 20 years of R&D experience and will focus on advancing pipeline programs. Buchanan will lead operations, manufacturing, and strategic initiatives, aiming for operational excellence as the company scales its business.

Silk Road Medical, Inc. (Nasdaq: SILK) announced positive results from the TransCarotid Artery Revascularization (TCAR) Surveillance Project, published in the Annals of Surgery. The study demonstrated lower rates of in-hospital complications such as myocardial infarction (0.5% for TCAR vs. 0.9% for carotid endarterectomy) and cranial nerve injury (0.4% vs. 2.7%). Outcome rates for in-hospital stroke and death were similar between the two procedures (1.6%). These findings may enhance TCAR's role in treating carotid artery stenosis, as stated by CEO Erica Rogers, supporting its adoption as the standard of care.